Portal Biotechnologies

Portal Biotechnologies is a private, platform technology company pioneering a novel physical method for intracellular delivery called 'Cell Squeeze®'. This technology enables the delivery of a wide range of cargo (proteins, nucleic acids, CRISPR components) into virtually any cell type, including hard-to-transfect primary immune cells, with high efficiency and viability. The company has rapidly gained traction with over 50 biopharma and academic partners, secured significant non-dilutive funding from DARPA, and completed an oversubscribed seed round. Portal's strategy involves selling research instruments (Gateway, Galaxy) to drive platform adoption while developing its own therapeutic programs and partnerships in cell therapy and immuno-oncology.

Proprietary membrane-based 'Cell Squeeze®' technology that uses mechanical disruption to enable efficient, reagent-free intracellular delivery of diverse cargo (proteins, nucleic acids, CRISPR components) into a wide variety of cell types, including primary immune cells.

Portal competes with viral vector companies, electroporation-based systems (e.g., MaxCyte, Lonza), and lipid nanoparticle (LNP) providers in the intracellular delivery space. Its key differentiation is its physical, reagent-free method that works across many cell and cargo types. Its closest competitor is likely SQZ Biotechnologies, founded by the same individual, which also uses a microfluidic constriction approach.